Ciclo celular/Ponto de verificação
Os inibidores do ciclo celular/ponto de verificação são compostos que interrompem a progressão normal do ciclo celular, particularmente em pontos de verificação regulatórios chave. Esses inibidores são cruciais para estudar a divisão celular, entender a proliferação de células cancerígenas e desenvolver terapias anticâncer. Ao direcionar fases específicas do ciclo celular, esses inibidores podem induzir a parada do ciclo celular, levando à apoptose ou senescência em células de divisão rápida. Na CymitQuimica, oferecemos uma ampla gama de inibidores de alta qualidade do ciclo celular/ponto de verificação para apoiar sua pesquisa em biologia do câncer, biologia celular e desenvolvimento de medicamentos.
Subcategorias de "Ciclo celular/Ponto de verificação"
- Aurora Quinase(94 produtos)
- CDK(500 produtos)
- Ciclo celular/Parada(4 produtos)
- Chk(42 produtos)
- DYRK(48 produtos)
- Dinamina(23 produtos)
- Ferroptose(215 produtos)
- HSP(169 produtos)
- Integrinas(224 produtos)
- Cinesina(66 produtos)
- LIM Quinase(19 produtos)
- Microtúbulo associado(261 produtos)
- PKC(102 produtos)
- PLK(28 produtos)
- ROCK(70 produtos)
- Rho(2 produtos)
- Wee1(15 produtos)
- c-Myc(69 produtos)
Exibir 10 mais subcategorias
Foram encontrados 3477 produtos de "Ciclo celular/Ponto de verificação"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PKMYT1-IN-3
<p>PKMYT1-IN-3 (compound 8ma) is a potent, selective inhibitor of PKMYT1, demonstrating an IC50 of 16.5 nM and exhibiting antitumor activity.</p>Fórmula:C24H26FN5O2Cor e Forma:SolidPeso molecular:435.49AB-3PRGD2
CAS:<p>AB-3PRGD2 is a radiolabeled agent that targets integrin αvβ3. It enhances tumor uptake and prolongs retention time in tumors, significantly improving the inhibition of tumor growth. AB-3PRGD2 also remodels the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells.</p>Fórmula:C137H215IN30O45SCor e Forma:SolidPeso molecular:3161.32CDK12-IN-6
CAS:<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Fórmula:C20H21F2N9Cor e Forma:SolidPeso molecular:425.448TLR7 agonist 12
CAS:<p>TLR7 agonist 12, a purine nucleoside analog, inhibits DNA synthesis and induces apoptosis in lymphoid cancers.</p>Fórmula:C14H19N5O8Cor e Forma:SolidPeso molecular:385.332-Methylbutyrylcarnitine chloride
<p>2-Methylbutyrylcarnitine (chloride) acts as a gut microbial metabolite that targets integrin α2β1 on platelets, facilitating the activation of cytosolic phospholipase A2 (cPLA2) and enhancing platelet hyperresponsiveness. This compound further augments platelet hyperreactivity and promotes thrombus formation in mice. It is also characterized as a branched-chain acylcarnitine.</p>Fórmula:C12H24ClNO4Cor e Forma:SolidPeso molecular:281.78Garenoxacin
CAS:<p>Garenoxacin (BMS284756) is a novel oral des-fluoro(6) quinolone for the treatment of Gram-positive and Gram-negative bacterial infections.</p>Fórmula:C23H20F2N2O4Pureza:98%Cor e Forma:SolidPeso molecular:426.41AURKA against 1
<p>Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.</p>Fórmula:C28H32FN9O2Cor e Forma:SolidPeso molecular:545.61m7GpppGmpG
CAS:<p>m7GpppGmpG, a trinucleotide 5′ cap analog, exhibits capping efficiencies of 86% for the RNAs obtained [1].</p>Fórmula:C32H43N15O25P4Cor e Forma:SolidPeso molecular:1161.66Pseudouridimycin
CAS:<p>Pseudouridimycin: a C-nucleoside antibiotic, inhibits bacterial RNAP, targets Gram-negative and Gram-positive bacteria.</p>Fórmula:C17H26N8O9Pureza:98%Cor e Forma:SolidPeso molecular:486.44Brr2-IN-2
<p>Brr2-IN-2 (Compound 30) is an inhibitor of Brr2, exhibiting an IC50 of 42 nM against Brr2 ATPase.</p>Fórmula:C21H25FN4O2Cor e Forma:SolidPeso molecular:384.45Ac-MRGDH-NH2
<p>Ac-MRGDH-NH2 is a pentapeptide containing the RGD sequence. It is utilized in the synthesis of the diastereomeric prodrugs Λ- and Δ-[Ru(Ph2phen)2(κS,κN-(Ac-MRGDH-NH2))]Cl2. In these prodrugs, Ac-MRGDH-NH2 serves as a photolabile protecting group for the cytotoxic diruthenium aqua complexes [Ru(Ph2phen)2(OH2)2]2+, offering integrin targeting and photoactivation properties. Consequently, Ac-MRGDH-NH2 can be applied in studies exploring tumor-targeted photoactivatable chemotherapy.</p>Fórmula:C25H41N11O8SCor e Forma:SolidPeso molecular:655.727Ribonuclease T1
CAS:<p>Rnase T1, an endonuclease, degrades single-stranded RNA to yield 3'-GMP oligonucleotides.</p>Cor e Forma:Solid5'-O-DMTr-5-MedC (Ac)-methyl phosphonamidite
<p>5’-O-DMTr-5-MedC (Ac)-methyl phosphonamidite, a purine nucleoside analog, exhibits broad antitumor activity, particularly against indolent lymphoid malignancies</p>Fórmula:C40H51N4O7PCor e Forma:SolidPeso molecular:730.832'-Deoxy-2'-fluoro-N3-[(pyrid-2-yl)methyl]uridine
<p>2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]uridine, a uridine analogue, exhibits potential for antiepileptic applications.</p>Fórmula:C15H16FN3O5Cor e Forma:SolidPeso molecular:337.3EFdA-TP
CAS:<p>EFdA-TP: potent HIV-1 RT inhibitor; acts via immediate/delayed chain termination (ICT/DCT) and multiple pathways.</p>Fórmula:C12H15FN5O12P3Cor e Forma:SolidPeso molecular:533.195HDAC-IN-85
<p>HDAC-IN-85 (Compound 1) is an HDAC inhibitor capable of crossing the blood-brain barrier. It exhibits inhibitory effects on brain tumor cell lines and can induce acetylation, resulting in DNA double-strand breaks and promoting RAD51 ubiquitination, which disrupts the DNA repair process. HDAC-IN-85 is applicable in studies of glioblastoma.</p>Fórmula:C24H27FN4O5Cor e Forma:SolidPeso molecular:470.49N1-Methyl-2'-β-C-methyl adenosine
<p>N1-Methyl-2’-beta-C-methyl adenosine, a purine nucleoside analog, exhibits broad antitumor activity, particularly against indolent lymphoid malignancies.</p>Fórmula:C12H17N5O4Cor e Forma:SolidPeso molecular:295.29Tetrahydromethotrexate
CAS:<p>Tetrahydromethotrexate is a folic acid derivative.</p>Fórmula:C20H26N8O5Cor e Forma:SolidPeso molecular:458.47αVβ8-IN-1
CAS:<p>αVβ8-IN-1 is an αVβ8 integrin inhibitor that suppresses the growth of multiple tumour cell lines (EMT6, CT26, KPC, TKCC-10).</p>Fórmula:C25H32ClN5O4Cor e Forma:SolidPeso molecular:502.01DNA Gyrase-IN-17
<p>DNA Gyrase-IN-17 (Compound 5C) is an inhibitor of DNA gyrase. It demonstrates significant antimicrobial activity against a range of Gram-positive and Gram-negative strains, including Enterococcus faecium, Escherichia coli, and Pseudomonas aeruginosa, with a MIC value of 62.5 μg/mL. By inhibiting bacterial DNA gyrase, DNA Gyrase-IN-17 disrupts DNA replication. This compound can be useful in the development of antibiotics, particularly for studying resistant strains.</p>Fórmula:C18H15ClFN5OCor e Forma:SolidPeso molecular:371.09492
